Congress Introduces Plant-Based Medicines Development Act for Cannabis

Bill Creates Schedule I Research Exemption

The Plant-Based Medicines Development Act establishes a statutory carve-out allowing FDA-supervised clinical trials of Schedule I botanicals without DEA rescheduling. The bill amends 21 U.S.C. § 823 to permit registered researchers to cultivate, process, and administer cannabis, psilocybin, and other controlled plant substances solely within FDA-sanctioned investigational new drug (IND) protocols. That's the strict reading.

The exemption applies exclusively to natural plant extracts and whole-plant formulations. Synthetic analogs? Still subject to standard DEA registration. Researchers must maintain separate cultivation facilities inspected quarterly by both DEA and FDA under the bill's dual-oversight framework.

For cannabis operators, the bill doesn't alter state-legal markets or IRC § 280E treatment. It targets pharmaceutical development pipelines, not dispensary supply chains.

Funding Mechanism Allocates $50M Annually

The bill authorizes $50 million in annual NIH appropriations for fiscal years 2027-2032, earmarked for plant-based medicine trials focused on PTSD, treatment-resistant depression, and chronic pain conditions. Grant priority goes to studies comparing whole-plant cannabis formulations against isolated cannabinoids—a direct challenge to the FDA's historical preference for single-molecule drugs.

The funding structure mirrors the 21st Century Cures Act model, with 60% allocated to academic institutions and 40% reserved for small biotech firms with fewer than 500 employees.

According to the bill text, grantees must publish raw efficacy data in public repositories within 18 months of trial completion. That transparency requirement addresses longstanding criticism that Schedule I restrictions have created a publication bias favoring negative cannabis studies.

State-Federal Coordination Remains Undefined

The bill's enforcement section delegates implementation to a joint DEA-FDA task force but provides no reconciliation mechanism for state-legal cannabis programs operating under conflicting regulatory standards. Researchers in California or Colorado would theoretically operate under both state cannabis laws and the new federal research framework. No explicit preemption language clarifies which regime controls.

The bill also omits any reference to existing state medical cannabis research programs, such as New York's clinical trials authorized under Public Health Law § 3369. That gap creates potential jurisdictional conflicts where state-approved trials might not qualify for federal exemptions if cultivation or dosing protocols diverge from FDA's investigational standards.

For a full breakdown of how this bill interacts with state regulatory frameworks, see the CannIntel topic hub on the Plant-Based Medicines Development Act.

The bill's cosponsors include members of both the House Energy and Commerce Committee and the Senate HELP Committee, signaling serious legislative intent. Floor consideration is expected in Q1 2027, though passage remains uncertain given the chamber's divided stance on broader cannabis reform.